Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Drop in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) saw a large drop in short interest in the month of January. As of January 30th, there was short interest totaling 63,632 shares, a drop of 29.8% from the January 15th total of 90,610 shares. Based on an average trading volume of 42,977 shares, the short-interest ratio is currently 1.5 days. Approximately 2.9% of the shares of the stock are sold short. Approximately 2.9% of the shares of the stock are sold short. Based on an average trading volume of 42,977 shares, the short-interest ratio is currently 1.5 days.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DWTX. Wall Street Zen cut Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Dogwood Therapeutics in a report on Friday, January 30th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $12.00.

Hedge Funds Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities & Exchange Commission. 9.05% of the stock is currently owned by hedge funds and other institutional investors.

Dogwood Therapeutics Stock Up 1.7%

Shares of DWTX traded up $0.05 during trading hours on Friday, reaching $3.07. 13,508 shares of the company traded hands, compared to its average volume of 37,126. The stock has a market capitalization of $7.04 million, a PE ratio of -0.12 and a beta of 1.88. The stock has a fifty day simple moving average of $3.95 and a 200 day simple moving average of $5.00. Dogwood Therapeutics has a fifty-two week low of $2.60 and a fifty-two week high of $14.69.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.